Academic Press Protein-Protein Interactions in Human Disease, Part B (Volume 111) (Advances in Protein Chemistry and Structural Biology, Volume 111)

Product Description Protein-Protein Interactions in Human Disease, Volume 111, Part B, promotes further research and development in the protein interaction network in order to identify critical proteins involved in the etiology of human diseases and locate new protein targets for drug development. Thus, this volume is of considerable interest to protein chemists, pharmacologists, cell biologists, immunologists, structural biologists, computational biochemists and other researchers working in the field. In addition, these articles would be of great benefit to medical, biology and pharmacology students who specialize in this field. Describes advances in the application of powerful techniques in studying and analyzing protein-protein interactions Ideal for a wide audience of researchers, specialists and students Written by authorities in their field Contains a number of high quality illustrations, figures and tables that support the presented information Review Presents an overview of advances in the role of protein-protein interactions in human diseases, along with new strategies for their treatment About the Author Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2010 Dr. Donev was appointed Senior Lecturer in Swansea University. Currently he is Head of Research at MicroPharm Ltd, UK and Director of Biomed Consult, UK. He has published more than 60 research papers, has chaired scientific meetings in Molecular Medicine and given plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on design of antibody-based oral treatment of pathological conditions of the colon and small intestines.